Overview
Title
To amend title XVIII of the Social Security Act to facilitate patient access to certain pediatric technologies.
ELI5 AI
H.R. 9157, called the "Access to Pediatric Technologies Act of 2024," is a plan to help kids get special medical tools by setting fair prices. It asks the government to make sure doctors can be paid properly when they use these tools for kids.
Summary AI
H.R. 9157, also known as the “Access to Pediatric Technologies Act of 2024,” aims to improve access to medical devices designed for children by providing a framework for establishing payment rates under Medicare. The bill instructs the Secretary of Health and Human Services to create national relative value units for eligible pediatric medical technologies that don't already have such rates, ensuring that these devices can be fairly compensated under the physician fee schedule. Manufacturers can request that their pediatric technologies be included, and the Secretary will use existing data, such as pricing and claims information, to set the rates. This legislation does not mandate that Medicare must cover the devices but seeks to facilitate their inclusion in the Medicare payment system if they are covered.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The bill under consideration, titled the "Access to Pediatric Technologies Act of 2024," aims to amend title XVIII of the Social Security Act. The primary objective is to improve patient access to certain pediatric medical technologies by establishing payment rates, known as national relative value units, under the existing physician fee schedule. This process is initiated upon request from the manufacturer of the technology and is set to come into effect for technologies provided on or after January 1, 2026. The legislation focuses specifically on medical devices predominantly used in pediatric procedures or those specifically designed for pediatric populations.
Significant Issues
A key issue with the bill is the ambiguity in the criteria defining a "qualifying pediatric technology." Terms like "predominantly performed on pediatric patients" or "specifically designed for safe and effective use in pediatric populations" could lead to varied interpretations, affecting consistent application across different technologies and manufacturers. Another concern is the potential administrative burden placed on the Secretary to establish national value units, which could lead to delays and obstruct timely access to these pediatric technologies. Additionally, the bill doesn't clarify how the Secretary will verify or access data from manufacturers, raising issues about data integrity and consistency. This lack of detail could result in unfair advantages for larger manufacturers capable of providing more comprehensive data.
Public Impact
For the general public, particularly families with pediatric patients, the bill could mean improved access to innovative medical technologies designed specifically for children. By setting clear payment rates, the bill may incentivize the development and availability of such technologies. However, the potential for administrative delays could initially hinder this access. Additionally, if value units do not accurately reflect the clinical benefits, there could be implications for the overall efficiency of healthcare funding, ultimately impacting taxpayers and those relying on these technologies for care.
Impact on Specific Stakeholders
For pediatric patients and their families, the bill holds promise for improved access to devices that could significantly enhance healthcare outcomes. Manufacturers of pediatric medical devices stand to benefit from more predictable reimbursement rates, which could encourage innovation and investment in the pediatric technology sector. However, smaller firms might find themselves at a disadvantage if they lack the resources to provide the required comprehensive data, potentially consolidating market power among larger companies. On the administrative side, the Department of Health may face increased workload and pressure to efficiently process requests and establish value units, which could strain resources unless adequately managed.
In summary, the bill represents a well-intentioned effort to enhance access to pediatric medical technologies, yet it faces challenges concerning definitions, administrative procedures, and equitable impacts across stakeholders. Careful attention to these issues will be crucial for the legislation to achieve its intended benefits without unintended negative consequences.
Issues
The definition and criteria for 'qualifying pediatric technology' in Section 2 could be ambiguous, particularly concerning when a device is 'used as part of a procedure predominantly performed on pediatric patients' or 'specifically designed for safe and effective use in pediatric populations.' This ambiguity may lead to inconsistencies in its application or potential challenges from stakeholders (Section 2, subsection 4).
The requirement for the Secretary to establish national relative value units under the physician fee schedule could impose additional administrative procedures, potentially leading to delays or increased administrative burdens. This might affect the timely access to pediatric technologies (Section 2, subsection 1 and 2).
The section does not specify how the Secretary will access or verify data provided by manufacturers, leading to potential data integrity issues or inconsistencies in determining value units. This could result in unfair economic advantages for certain manufacturers (Section 2, subsection 2B and 3C).
There is a potential for bias towards manufacturers able to provide more comprehensive data, favoring larger companies with more resources. This could create a competitive disadvantage for smaller manufacturers (Section 2, subsection 3C).
The timeline for establishing national relative value units following a manufacturer's request could delay the implementation of new technologies, depending on when the request is received within the year, potentially affecting patient access (Section 2, subsection 3B).
The provision may lead to wasteful spending if the established value units do not accurately reflect the economic value or clinical benefits of pediatric technologies, impacting the overall effectiveness and efficiency of healthcare funding (Section 2, subsection 2).
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of this act states its name, which is the “Access to Pediatric Technologies Act of 2024”.
2. Facilitating access to pediatric technologies Read Opens in new tab
Summary AI
For pediatric technologies that are used in medical procedures for children, this section requires the Secretary to establish payment rates, known as national relative value units, if requested by the manufacturer. These rates will be determined using various data and must follow existing payment rules.